statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging Growth Conference on April 3 & 4, 2024. The...

Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now

MIAMI, April 02, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging Growth Conference on April 3 & 4, 2024...

Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now

In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on Dermata Therapeutics (DRMA Research Report). The com...

Maxim Group Sticks to Their Buy Rating for Dermata Therapeutics (DRMA)

- Dermata to provide a corporate update followed by a live question and answer session -SAN DIEGO, CA / ACCESSWIRE / March 27, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ('Dermata' or the...

Dermata to Present at the Emerging Growth Conference on April 3, 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Dermata Therapeutics just reported results for the fourth quarter of 2023.
The post DRMA Stock Earnings: Dermata Therapeutics Reported...

DRMA Stock Earnings: Dermata Therapeutics Reported Results for Q4 2023

- Initiated enrollment of DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial in Q4 2023 -- Raised $9.1 million in gross proceeds from three financings completed in 2023...

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results

MIAMI, Feb. 07, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 67th Emerging Growth Conference on February 7 & 8, 2024. The...

Presenting on the Emerging Growth Conference 67 Day 2 on February 8 Register Now

MIAMI, Feb. 06, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 67th Emerging Growth Conference on February 7 & 8, 2024. The...

Presenting on the Emerging Growth Conference 67 Day 1 on February 7 Register Now

- Company to provide a corporate overview followed by a live question and answer session -SAN DIEGO, CA / ACCESSWIRE / February 1, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW...

Dermata to Present at the Emerging Growth Conference on February 7, 2024

Shares of Dermata Therapeutics, Inc. (NASDAQ: DRMA) rose sharply in pre-market trading after the company announced the issuance of a new patent in Japan for its DMT410 program for the treatment of...

Why Dermata Therapeutics Shares Are Trading Higher By Over 57%; Here Are 20 Stocks Moving Premarket

Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. Its product pipeline includes DMT310, DMT400, and DMT410. The company was founded by David F. Hale and Gerald T. Proehl on December 8, 2014 and is headquartered in San Diego, CA.

Volume	31,197.00
52-Wk High	$3.68
52-Wk Low	$0.232

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.36	--	--	N/A
Q4'23	-$0.78	--	--	N/A
Q3'23	-$0.63	-$0.54	14.29%	BEAT
Q2'23	-$0.92	-$0.63	31.52%	BEAT
Q1'23	-$2.65	--	--	N/A

DRMA Dermata Therapeutics Inc

About

Feed

News

Earnings

Fundamentals